,
your personalized virtual assistant to find clinical trials. Go head, 
Robert Raju, MD
Dayton Oncology & HematologyKettering, Ohio - 45409 (937-528-0317) Dayton Oncology And HematologyKettering, Ohio - 45409 |
- CLINICAL TRIALS 2
- CONDITIONS4
- INTERVENTIONS8
- SINCE2006
Safety and Tolerability Study of PCI-32765 in Chronic Lymphocytic Leukemia
May 2010 - December 2011
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
May 2006 -
Lymphoma
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Pci-32765
Cgc-11047 And Gemcitabine
Cgc-11047 And Docetaxel
Cgc-11047 And Bevacizumab
Cgc-11047 And Erlotinib
Cgc-11047 And Cisplatin
Cgc-11047 And 5-Flurouracil / Leucovorin
Cgc-11047 And Sunitinib
